Considering the significant increase of MTAP deficiency from pT2 (22.2%) to pT3 (30.0%) and pT4 (31.2%) carcinomas in our earlier study14, we would speculate that the rather high rate of MTAP deficient cancers in our present series is caused by a selection of large tumors with availability of as many as possible tumor containing tissue blocks for constructing a heterogeneity TMA and potentially also by the relatively low number of cases (n = 41) in our consecutive series. This evidence concerns the gene MTAP and cancer.